Latest Market Entry News

HITIQ Limited reported a $2.9 million loss for the half-year ending December 2025, while making significant strides in international market expansion and strategic partnerships. The company’s capital raising efforts aim to support its transition from technology validation to commercial execution.

Epiminder Limited has reported a $21.7 million loss for the half-year ending December 2025, alongside a successful $125 million IPO that fuels its commercialisation of the FDA-approved Minder epilepsy monitoring device.

Orthocell Limited has reported a record half-year revenue of $6.2 million, driven by accelerating sales of its regenerative medicine products and expanding global footprint. The company’s US commercial launch of Remplir™ is gaining momentum alongside new market entries in Canada, Hong Kong, and Europe.

RLF AgTech has secured strategic distribution partnerships with two leading Indian agricultural groups, marking its commercial entry into one of the world’s largest crop nutrition markets. These agreements position RLF for rapid expansion in India’s vast and growing agricultural sector.

Paradigm Biopharmaceuticals has drawn down US$5 million from its Convertible Note Facility to fund the next phase of its global Phase 3 trial for knee osteoarthritis treatment, marking a key step as patient recruitment nears 50%.

Cleo Diagnostics has chosen Bio-Techne’s next-generation Ella™ platform to enhance its ovarian cancer blood test, aiming for faster, more precise results and a streamlined path to FDA approval.

Telix Pharmaceuticals has lodged a European marketing authorization application for TLX101-Px, a novel PET imaging agent targeting glioma brain cancer, aiming to enhance diagnostic precision and patient access across major European markets.

Osteopore Limited has secured an exclusive three-year distribution deal with Medprin Biotech GmbH to broaden its presence in Latin America's craniofacial reconstruction market, tapping into a region poised for significant growth.

Temple & Webster Group Limited reported a robust 20% revenue increase to $376 million in the first half of FY26, maintaining momentum towards its $1 billion revenue target by FY28. The company’s strategic investments in AI, exclusive products, and new markets like New Zealand underpin its expanding market presence.

Temple & Webster has reported a robust 20% increase in half-year revenue to $376 million, expanding its market share and launching successfully into New Zealand. EBITDA remains within guidance despite new market investments.

Temple & Webster reported a 20% revenue increase to $375.9 million for H1 FY26, driven by record active customers and exclusive product growth. However, profit before tax fell 25% to $9.4 million, impacted by investments in New Zealand and higher marketing spend.

Janus Electric has landed further orders worth approximately A$1.6 million from its authorised California dealer, Electric Vehicle Choice, marking a significant step in its U.S. market expansion. The orders include conversion modules, batteries, and charging infrastructure, with shipment planned for mid-2026.